PDCD1 and melanoma: A Phase I study by Sahin et al. of an intravenously administered mix of four non-mutated shared melanoma mRNA TAAs (BNT-111: NY-ESO-1, MAGE-A3, tyrosinase and transmembrane phosphatase with tensin homology (TPTE)) delivered by LPX liposomes (FixVAC) with unresectable melanoma patients previously treated with ICIs reported potent and durable CD4+ and CD8+ antigen-specific T-cell responses in the presence or absence of co-administered anti PD-1 therapy [62].